NAD+ & NMN for Eye Health (Glaucoma, AMD): The Evidence

If you search "NAD+ for eyes," you'll hit two very different worlds. One is a genuine, randomized-trial story about a specific form of vitamin B3 protecting the optic nerve in glaucoma. The other is supplement marketing that quietly borrows that credibility to sell NMN capsules for "eye health," macular degeneration, and "vision longevity" — claims the human evidence does not support. The honest version separates them carefully, because they are not the same molecule, not the same disease, and not the same level of proof.

Here's the one-line version to anchor everything below: in glaucoma, nicotinamide (a form of vitamin B3) has real human randomized-trial evidence for improving the optic nerve's function — but for age-related macular degeneration (AMD), and for NMN specifically, the supportive data are still animal and cell-culture only.

Why the eye is an NAD+ story at all

The retina is, gram for gram, one of the most metabolically demanding tissues in the body. The retinal ganglion cells — whose long axons bundle together to form the optic nerve — are packed with mitochondria and burn through enormous amounts of energy to keep firing. That makes them exquisitely dependent on NAD+, the central coenzyme of mitochondrial energy production, and unusually vulnerable when NAD+ supply falls. The foundational demonstration came from a 2017 mouse study in Science: in aged mice genetically prone to glaucoma, retinal NAD+ declined with age, and supplementing nicotinamide (vitamin B3, an NAD+ precursor) robustly protected the retinal ganglion cells and prevented glaucoma from developing ¹. Follow-up mechanistic work confirmed the throughline — nicotinamide guards these neurons against the mitochondrial and metabolic dysfunction that drives their death ⁵, and reviews now frame the NAD+/NADH redox state as both a candidate biomarker and a therapeutic target in glaucoma ⁶.

That biology is legitimate, and unlike most "NAD+ for X" pitches, it has actually been carried into human trials for one disease.

Glaucoma: where the human RCT evidence is real

This is the strong part of the story, and it deserves to be stated plainly. Nicotinamide has been tested in randomized, placebo-controlled human trials in glaucoma, and it improved a measure of how well the inner retina works.

In a crossover randomized trial, glaucoma patients already on pressure-lowering treatment took high-dose nicotinamide; their inner retinal function — measured electrophysiologically — improved versus placebo, an early but genuine human signal that the mouse biology translates ². A larger and more rigorous step followed: a Phase 2 randomized clinical trial in JAMA Ophthalmology combined nicotinamide with pyruvate in people with open-angle glaucoma and reported a measurable improvement in visual field — actual sight-relevant function — over the trial period versus placebo ³. And in 2026, a crossover placebo-controlled randomized trial in normal-tension glaucoma (where eye pressure is already in the normal range, so the benefit can't be chalked up to pressure-lowering) again tested nicotinamide supplementation, extending the evidence into a population where conventional therapy is hardest ⁴. A six-month study also reported improvements in glaucoma patients' quality of life on niacinamide ¹⁰.

Read together, these are the rare case where the NAD+ supplement story has actual randomized human evidence behind it. But the caveats matter for honesty:

• •The doses used are high pharmacological doses of nicotinamide (multiple grams per day in the trials), not a casual multivitamin amount — and high-dose niacinamide needs medical supervision and liver-enzyme monitoring.
• •The endpoints so far are function measures (inner-retinal electrophysiology, visual-field metrics over months), not yet proof that nicotinamide prevents long-term blindness or replaces pressure-lowering therapy.
• •In every trial, nicotinamide was added on top of standard glaucoma treatment — it is an adjunct under study, not a standalone cure.

So the accurate framing is: nicotinamide is one of the most promising neuroprotective adjuncts in glaucoma, with multiple positive randomized trials on functional endpoints — but it is still investigational, dosed in gram quantities, and not a substitute for seeing an ophthalmologist.

AMD and the retina: real biology, animal-only data

Now the part the marketing blurs. Age-related macular degeneration is a different disease — degeneration of the macula and retinal pigment epithelium (RPE), not the optic nerve — and here the NAD+ evidence drops a full tier, to animals and cells.

The mechanistic rationale is real: NAD+ supports the highly energy-dependent photoreceptors and RPE, and in a mouse model, NAD+ maintenance attenuated light-induced photoreceptor degeneration ⁸. For the RPE specifically, nicotinamide mononucleotide (NMN) reduced cellular senescence and inflammation in a sodium-iodate model of RPE damage used to mimic AMD-like injury ⁹. Nicotinamide riboside (NR), another precursor, preserved retinal ganglion cells in a glutamate-toxicity cell model ⁷. These are encouraging — but every one of them is in mice or in a dish. There is no randomized human trial showing that NMN, NR, or NAD+ slows AMD progression, preserves macular vision, or improves any sight outcome in people with macular degeneration. That gap is the entire difference between "biologically plausible" and "proven."

This is also where the molecule swap matters. The human glaucoma trials used nicotinamide (and in one case nicotinamide plus pyruvate) — not NMN. NMN reliably raises blood NAD+ in people, but its eye data are confined to animal RPE and photoreceptor models ⁹. So a bottle of NMN sold for "eye health" is borrowing evidence that belongs to a different B3 form, used for a different eye disease, at a clinically supervised dose.

What this means if you actually care about your eyes

A few honest takeaways:

1. 1.If you have glaucoma — especially normal-tension glaucoma — high-dose nicotinamide is a legitimate thing to ask your ophthalmologist about, because there are real randomized trials behind it ²³⁴. But the dose is pharmacological, it needs monitoring, and it's an add-on to (never a replacement for) pressure-lowering treatment.
2. 2.If your goal is preventing or slowing AMD, the NAD+/NMN evidence is animal-only ⁸⁹. The thing with actual human AMD trial evidence is the AREDS2 antioxidant formula — not an NAD+ precursor.
3. 3.NMN specifically has no human eye-disease trial. Buying NMN for "vision" is acting on mouse RPE data and on glaucoma trials that used a different compound.

Bottom line

The eye is a genuine NAD+ story, but the honest grade splits sharply by disease and by molecule. For glaucoma, nicotinamide (vitamin B3) has multiple randomized human trials showing improved retinal function and visual-field measures — making it one of the few NAD-related supplements with real human evidence, though still high-dose, investigational, and adjunctive ¹²³⁴. For AMD and the broader retina, and for NMN specifically, the protective data are striking but confined to animals and cell culture ⁸⁹ — no human outcome trial exists. Treat glaucoma nicotinamide as a promising adjunct to discuss with an eye doctor, and treat NMN-for-vision as unproven marketing. For the broader picture, see our pillar guide to NAD+ therapy, our honest look at whether NAD+ is really anti-aging, the parallel skin story in NAD+ for skin, and where products land in the best NAD+ supplements.

This is consumer education, not medical advice. The glaucoma trials used high pharmacological doses of nicotinamide under medical supervision; do not self-treat any eye disease. If you have glaucoma, macular degeneration, or any vision change, see an ophthalmologist.